Answers are grounded in this paper and cite their sources.
Retrospective review identifies distinct characteristics and outcomes of uncommon EGFR mutations in lung cancer, suggesting tailored treatment strategies.
Abstract Introduction : The optimal treatment of uncommon, compound EGFR-mutated NSCLC is poorly defined due to heterogeneous responses to targeted therapies. Methods : We retrospectively reviewed patient characteristics and treatment outcomes from cohorts of advanced EGFR-mutated NSCLC patients at UC San Diego Health and the American Association of Cancer Research GENIE database. Results : In our institutional cohort, L858R-mutated patients were significantly more likely to have a de novo compound mutation than those with exon19del (24/159 [15%] vs 4/228 [2%], P < 0.01). Conversely, acquired C797S mutations more often co-occurred with exon19del after osimertinib progression compared to L858R (23/113 [20%] vs 6/89 [7%], P < 0.01). In the GENIE database, 88% of patients with S768I mutations had an additional EGFR co-mutation, most commonly G719X. Osimertinib time to treatment failure (TTF) varied notably in our institutional cohort: patients with co-mutated G719X/L861Q exhibited a median TTF > 13 months and those with G719X alone had a median TTF < 7 months. Conclusion : Our findings demonstrate that compound EGFR mutations comprise distinct subgroups with unique clinical characteristics and differential responses to targeted therapy. For example, osimertinib may be a viable treatment for patients with compound G719X/L861Q mutations. Further characterization of these heterogeneous subgroups is warranted for identifying optimal treatment strategies as novel targeted agents emerge.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: